CO2020010188A2 - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents

Anticuerpos agonistas contra pd-1 y usos de estos

Info

Publication number
CO2020010188A2
CO2020010188A2 CONC2020/0010188A CO2020010188A CO2020010188A2 CO 2020010188 A2 CO2020010188 A2 CO 2020010188A2 CO 2020010188 A CO2020010188 A CO 2020010188A CO 2020010188 A2 CO2020010188 A2 CO 2020010188A2
Authority
CO
Colombia
Prior art keywords
antibodies against
agonist antibodies
antibodies
tissues
human
Prior art date
Application number
CONC2020/0010188A
Other languages
English (en)
Inventor
Qing Chai
Yiqing Feng
Stephanie Marie Truhlar
Petra Verdino
Pia Pauliina Yachi
Kristin Paige Newburn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2020010188A2 publication Critical patent/CO2020010188A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos agonistas anti-PD-1 humana y sus usos para tratar trastornos autoinmunitarios, tales como la artritis reumatoide, o para disminuir el rechazo de células y/o tejidos trasplantados.
CONC2020/0010188A 2018-03-02 2020-08-19 Anticuerpos agonistas contra pd-1 y usos de estos CO2020010188A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
PCT/US2019/019076 WO2019168745A1 (en) 2018-03-02 2019-02-22 Pd-1 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2020010188A2 true CO2020010188A2 (es) 2020-08-31

Family

ID=65686121

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010188A CO2020010188A2 (es) 2018-03-02 2020-08-19 Anticuerpos agonistas contra pd-1 y usos de estos

Country Status (26)

Country Link
US (1) US10493148B2 (es)
EP (1) EP3759139A1 (es)
JP (3) JP7071521B2 (es)
KR (2) KR102536014B1 (es)
CN (1) CN111886253A (es)
AR (1) AR114127A1 (es)
AU (2) AU2019228474B2 (es)
BR (1) BR112020015983A2 (es)
CA (1) CA3092064C (es)
CL (1) CL2020002180A1 (es)
CO (1) CO2020010188A2 (es)
CR (1) CR20200375A (es)
DO (1) DOP2020000153A (es)
EA (1) EA202091809A1 (es)
EC (1) ECSP20053544A (es)
IL (1) IL276340A (es)
JO (1) JOP20200210A1 (es)
MA (1) MA52414A (es)
MX (1) MX2020009124A (es)
PE (1) PE20210045A1 (es)
PH (1) PH12020551463A1 (es)
SA (1) SA520420082B1 (es)
SG (1) SG11202008437WA (es)
TW (1) TWI708787B (es)
WO (1) WO2019168745A1 (es)
ZA (1) ZA202004601B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362074B1 (en) * 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
KR20200014414A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US20210061912A1 (en) * 2018-03-20 2021-03-04 WuXi Biologics Ireland Limited Novel anti-pd-1 antibodies
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023522962A (ja) * 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Ｐｄ－１アゴニスト多量体結合分子
EP4159235A1 (en) * 2020-05-25 2023-04-05 Foundation for Biomedical Research and Innovation at Kobe Pd-1 agonist-containing pharmaceutical composition for treating or preventing th2-mediated disease
JP2023528778A (ja) 2020-05-26 2023-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
CA3217199A1 (en) 2021-05-13 2022-11-17 Foundation For Biomedical Research And Innovation At Kobe Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
US20230312743A1 (en) 2021-11-19 2023-10-05 Mirobio Limited Engineered pd-1 antibodies and uses thereof
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2024040206A2 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
WO2024050421A2 (en) * 2022-08-30 2024-03-07 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting programmed cell death protein 1 (pd-1)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
EP2342228B1 (en) * 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
EP3177644B1 (en) * 2014-08-05 2020-10-07 Mabquest SA Immunological reagents binding to pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
EP3313883B1 (en) 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
KR20180054824A (ko) * 2015-09-29 2018-05-24 셀진 코포레이션 Pd-1 결합 단백질 및 이의 사용 방법
EP3356404B1 (en) 2015-10-02 2021-08-18 F. Hoffmann-La Roche AG Anti-pd1 antibodies and methods of use
MX2018003936A (es) 2015-10-02 2018-07-06 Symphogen As Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
EP3383412A4 (en) 2015-12-02 2019-06-05 Stcube, Inc. SPECIFIC ANTIBODIES OF GLYCOSYLATED PD-1 PROTEIN AND METHODS OF USE
KR20200014414A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법

Also Published As

Publication number Publication date
CN111886253A (zh) 2020-11-03
EP3759139A1 (en) 2021-01-06
CA3092064A1 (en) 2019-09-06
MA52414A (fr) 2021-01-06
TWI708787B (zh) 2020-11-01
JOP20200210A1 (ar) 2020-08-30
TW201942133A (zh) 2019-11-01
KR102536014B1 (ko) 2023-05-24
JP2022088411A (ja) 2022-06-14
JP7259107B2 (ja) 2023-04-17
SG11202008437WA (en) 2020-09-29
DOP2020000153A (es) 2020-09-15
AU2023204569A1 (en) 2023-10-26
ECSP20053544A (es) 2020-10-30
CR20200375A (es) 2020-09-25
KR20200115614A (ko) 2020-10-07
BR112020015983A2 (pt) 2020-12-15
AU2019228474B2 (en) 2023-04-13
IL276340A (en) 2020-09-30
AR114127A1 (es) 2020-07-22
CL2020002180A1 (es) 2021-01-04
KR20230079458A (ko) 2023-06-07
PH12020551463A1 (en) 2021-09-01
SA520420082B1 (ar) 2022-11-11
WO2019168745A1 (en) 2019-09-06
EA202091809A1 (ru) 2020-11-23
ZA202004601B (en) 2022-03-30
US20190270818A1 (en) 2019-09-05
CA3092064C (en) 2024-01-02
JP7071521B2 (ja) 2022-05-19
PE20210045A1 (es) 2021-01-08
MX2020009124A (es) 2020-09-28
US10493148B2 (en) 2019-12-03
AU2019228474A1 (en) 2020-08-20
JP2023093549A (ja) 2023-07-04
JP2021516235A (ja) 2021-07-01

Similar Documents

Publication Publication Date Title
CO2020010188A2 (es) Anticuerpos agonistas contra pd-1 y usos de estos
ECSP17085333A (es) Anticuerpos anti-cd40 y sus usos.
CL2021001573A1 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos.
PE20211594A1 (es) Anticuerpos biespecificos contra el a-beta humano y el receptor de transferrina humano y metodos de uso
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
UY33728A (es) ?VARIANTES DE Fc SILENCIOSAS DE LOS ANTICUERPOS ANTI-CD40?.
CL2021001661A1 (es) Compuestos de heterociclil piridazina como fungicidas
AR068354A1 (es) Anticuerpos contra el receptor del linfona de burkitt (anti- cxcr5) humanizados, derivados de los mismos y su uso
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CL2020002613A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
CL2017002106A1 (es) Anticuerpos contra tau y sus usos
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
ECSP12011980A (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
AR117566A1 (es) Anticuerpos anti-trem-1 y sus usos
EA201892005A1 (ru) Композиции и способы для лечения ревматоидного артрита
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
CL2021000606A1 (es) Anticuerpos agonistas contra cd200r y sus usos
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
ECSP22041169A (es) Anticuerpos trem2 y usos de estos
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
UY39111A (es) Compuestos para su uso en afecciones autoinmunitarias
Melkumyan TO THE QUESTION OF THE STRUCTURE OF THE EDUCATIONAL FUNCTION OF THE LEGAL RESPONSIBILITY